In fact, in a review of the relationship between hypertension and the use of angiotensin-converting enzyme (ACE) inhibitors with COVID-19 outcomes, the authors argue that there is no evidence to support the hypothesis that hypertension or inhibitors of the renin-angiotensin system contribute to unfavorable outcomes in viral infections [31]. Here, ACE is linked to viral infectious disease.